Landscape Capital Management L.L.C. Makes New $913,000 Investment in Palisade Bio, Inc. $PALI

Landscape Capital Management L.L.C. acquired a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 436,726 shares of the company’s stock, valued at approximately $913,000. Landscape Capital Management L.L.C. owned about 0.25% of Palisade Bio at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Perceptive Advisors LLC purchased a new position in shares of Palisade Bio in the 4th quarter valued at $28,318,000. Commodore Capital LP purchased a new stake in Palisade Bio in the fourth quarter valued at $26,896,000. Janus Henderson Group PLC purchased a new stake in Palisade Bio in the fourth quarter valued at $24,822,000. BlackRock Inc. acquired a new position in Palisade Bio in the second quarter valued at $21,813,000. Finally, RA Capital Management L.P. acquired a new position in Palisade Bio in the fourth quarter valued at $16,742,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Insider Buying and Selling

In other Palisade Bio news, insider Mitchell Lawrence Jones sold 51,880 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total value of $106,354.00. Following the transaction, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. The trade was a 35.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John David Finley sold 146,798 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total transaction of $303,871.86. Following the transaction, the chief executive officer owned 217,555 shares of the company’s stock, valued at approximately $450,338.85. The trade was a 40.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders purchased a total of 125,000 shares of company stock valued at $250,100 over the last three months. 0.07% of the stock is currently owned by company insiders.

Palisade Bio Price Performance

PALI opened at $2.10 on Monday. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86. The business has a 50 day moving average price of $1.99 and a two-hundred day moving average price of $1.93. The company has a market cap of $365.97 million, a PE ratio of -4.38 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Monday, August 10th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, sell-side analysts expect that Palisade Bio, Inc. will post -0.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PALI shares. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Oppenheimer started coverage on Palisade Bio in a research report on Thursday, July 23rd. They set an “outperform” rating and a $8.00 price target on the stock. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.00.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.